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Characterization of the plasma proteome 
of nonhuman primates during Ebola virus 
disease or melioidosis: a host response 
comparison
Michael D. Ward1, Ernst E. Brueggemann1, Tara Kenny1, Raven E. Reitstetter1, Christopher R. Mahone1, 
Sylvia Trevino2, Kelly Wetzel1, Ginger C. Donnelly1, Cary Retterer1, Robert B. Norgren Jr.3, Rekha G. Panchal1, 
Travis K. Warren1, Sina Bavari1 and Lisa H. Cazares1* 
Abstract 
Background: In-depth examination of the plasma proteomic response to infection with a wide variety of pathogens 
can assist in the development of new diagnostic paradigms, while providing insight into the interdependent patho-
genic processes which encompass a host’s immunological and physiological responses. Ebola virus (EBOV) causes a 
highly lethal infection termed Ebola virus disease (EVD) in primates and humans. The Gram negative non-spore form-
ing bacillus Burkholderia pseudomallei (Bp) causes melioidosis in primates and humans, characterized by severe pneu-
monia with high mortality. We sought to examine the host response to infection with these two bio-threat pathogens 
using established animal models to provide information on the feasibility of pre-symptomatic diagnosis, since the 
induction of host molecular signaling networks can occur before clinical presentation and pathogen detection.
Methods: Herein we report the quantitative proteomic analysis of plasma collected at various times of disease 
progression from 10 EBOV-infected and 5 Bp-infected nonhuman primates (NHP). Our strategy employed high 
resolution LC–MS/MS and a peptide-tagging approach for relative protein quantitation. In each infection type, for 
all proteins with > 1.3 fold abundance change at any post-infection time point, a direct comparison was made with 
levels obtained from plasma collected daily from 5 naïve rhesus macaques, to determine the fold changes that were 
significant, and establish the natural variability of abundance for endogenous plasma proteins.
Results: A total of 41 plasma proteins displayed significant alterations in abundance during EBOV infection, and 28 
proteins had altered levels during Bp infection, when compared to naïve NHPs. Many major acute phase proteins 
quantitated displayed similar fold-changes between the two infection types but exhibited different temporal dynam-
ics. Proteins related to the clotting cascade, immune signaling and complement system exhibited significant differen-
tial abundance during infection with EBOV or Bp, indicating a specificity of the response.
Conclusions: These results advance our understanding of the global plasma proteomic response to EBOV and Bp 
infection in relevant primate models for human disease and provide insight into potential innate immune response 
differences between viral and bacterial infections.
Keywords: Ebola virus, Burkholderia pseudomallei, Quantitative plasma proteomics
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Background
Ebola virus (EBOV) causes a highly virulent systemic 
disease, Ebola virus disease (EVD) that results in hem-
orrhagic fever (in both primates and humans) with high 
fatality rates. Outbreaks of EVD occur primarily in Sub-
Saharan Africa, and EBOV (formerly designated as Zaire 
ebolavirus) is responsible for the largest number of out-
breaks of the five known members of the Ebolavirus 
genus, including the first documented outbreak which 
occurred in 1976, and the largest outbreak which started 
in 2013 and was finally contained in 2015 (est. 28,000 
cases) [1, 2]. In humans, the general symptomatic pro-
file of EVD resembles that of malaria, yellow fever, Lassa 
fever and typhoid fever, which are also endemic to Sub-
Saharan Africa, thus complicating diagnosis and contain-
ment efforts [3]. Although PCR-based blood diagnostic 
methods have been improved to detect the presence of 
EBOV RNA, most PCR-based assays do not reach reli-
able detection levels until 72 h after infection, depending 
on viral load [4], and a negative PCR in the first 3 days of 
illness onset does not exclude EBOV infection.
NHP models of EBOV infection have provided the 
most informative data related to the pathology and host 
response. In rhesus (Macaca mulatta) and cynomol-
gus (Macaca fascicularis) macaques infected with 1000 
PFU of EBOV (intramuscular route), viremia is initially 
detected 3–4  days after infection, often coinciding with 
a febrile response [5, 6]. Monocytes/macrophages and 
dendritic cells are the first cell types that are infected; 
virus then spreads to the regional lymph nodes, liver and 
spleen by the movement of infected cells and free virus 
into the bloodstream. Lymphopenia, thrombocytope-
nia, neutrophilia and coagulopathy develop as EVD pro-
gresses [7, 8] along with a pro-inflammatory cytokine/
chemokine response [9].
Melioidosis is an illness caused by the soil-dwelling 
Gram negative non-spore forming bacillus Burkholde-
ria pseudomallei (Bp) which afflicts both humans and 
animals [10]. Most cases originate in Southeast Asia 
and Northern Australia where it is a common cause of 
pneumonia, likely due to aerosolization during mon-
soon rainfall [11]. A low infectious dose by the aerosol 
route with the potential for rapid, severe and frequently 
fatal pneumonia makes Bp a bio-threat that necessitates 
rapid diagnostic strategies. Melioidosis has varied clinical 
presentations in both humans and non-human primates, 
including asymptomatic infection, localized skin ulcers/
abscesses, chronic pneumonia, and fulminant septic 
shock with abscesses in multiple internal organs [12, 13]. 
Treatment of melioidosis is difficult, due to the fact that 
Bp is naturally resistant to multiple antibiotics and pro-
longed antibiotic treatment (5–6 months) is necessary to 
prevent relapse.
Although there is no universally accepted NHP model 
for melioidosis, upon aerosol exposure with Bp, rhe-
sus macaques develop progressive pneumonia and 
sepsis similar to the disease course in humans [14, 15]. 
%e infection can be lethal in rhesus macaques, but 
like humans, NHPs vary greatly in their response to Bp 
infection and many develop sub-acute pneumonia. Bp 
is an intracellular pathogen that can multiply within 
phagocytes, including neutrophils, monocytes and mac-
rophages without activating a bactericidal response [16, 
17]. Localized disease, such as pneumonia and abscesses 
are typical in both human cases and the NHP model; 
however, Bp can spread to secondary sites, including 
liver, spleen and brain, or to the blood, and often results 
in chronic persistent infection [18, 19]. %ere have been 
few reports examining the transcriptomic or proteomic 
response to melioidosis in humans [20–22].
Characterizing the host response to infection theoreti-
cally holds promise for pre-symptomatic diagnosis, since 
the induction of host molecular signaling networks often 
occurs before clinical presentation and pathogen detec-
tion [23]. Specifically, analyzing changes in host gene and 
protein expression during infection can generate patho-
gen-specific biomarker profiles, as different infectious 
agents may elicit distinct responses. %e interrogation of 
the circulatory host response to EBOV or Bp infection in 
humans has been performed on a small number of sam-
ples, and is further complicated by supportive care treat-
ments [24–27]. %erefore, the use of comparable NHP 
models is necessary for the characterization of the plasma 
proteomic response. Furthermore, in-depth examination 
of the host response to various pathogenic organisms 
generates information that extends beyond simple diag-
nosis, especially in the context of animal model devel-
opment and therapeutic evaluation. For example, 
blood-based host response markers of infection (genetic 
or protein-based) can be used to better define pathogen-
esis, stratify disease states and define specific trigger-to-
treat paradigms for new therapeutic treatments in animal 
models of infection. Furthermore the examination of the 
temporal kinetics of the host response during infection 
provides data related to virulence determination allowing 
for the down-selection of strains or isolates used as chal-
lenge material for animal model studies.
To track and characterize plasma proteomic host 
response dynamics, we examined serially collected sam-
ples from 10 rhesus macaques during EBOV infection 
and 5 rhesus macaques during Bp infection. Our strategy 
employed high resolution LC–MS/MS and a peptide-
tagging approach for relative protein quantitation. %ese 
studies provide a detailed characterization of the blood-
based host proteomic response profile to EBOV and Bp 
infection in NHP models which approximate EVD and 
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melioidosis in humans, and highlight the differences 
in the innate immune response to a lethal viral versus a 
pathogenic bacteria.
Materials and methods
Animal use and ethics statement
All NHP studies were conducted under an IACUC-
approved protocol in compliance with the Animal Wel-
fare Act, PHS Policy, and other Federal statutes and 
regulations relating to animals and experiments involving 
animals. %e facility where this research was conducted is 
accredited by the Association for Assessment and Accred-
itation of Laboratory Animal Care, International and 
adheres to principles stated in the Guide for the Care and 
Use of Laboratory Animals, National Research Council, 
2011. Research was conducted under IACUC-approved 
protocols in compliance with the Animal Welfare Act, 
PHS Policy, and other Federal statutes and regulations 
relating to animals and experiments involving animals.
EBOV infection
Ten adult rhesus macaques (6 male and 4 female, weight 
4.7–5.6 kg, average age 4.2 years) were inoculated with a 
target titer of 1000 plaque-forming units (PFU) of EBOV 
(H.sapiens-tc/COD/1995/Kikwit-9510621 (15) demon-
strated to be primarily the 8U variant at the mRNA edit-
ing site) in 0.5 mL by intramuscular (IM) injection in the 
left or right quadricep. %ese animals served as control 
animals in therapeutic studies, and the samples were ret-
rospectively analyzed to characterize the proteomic host 
response to EBOV infection. In all animals, plasma col-
lection occurred on Day 0 (pre-infection) and Days 2, 3, 
4, 5 and 6 post-infection. All EBOV studies were con-
ducted in Animal Biosafety Level 4 containment. Begin-
ning on Day 0 and continuing for the duration of the 
in-life phase, clinical observations were recorded, and 
animals were closely monitored for disease progression. 
Moribund animals were humanely euthanized based on 
institutional-approved clinical scoring and pre-deter-
mined endpoints.
EBOV RT-PCR
For quantitative assessment of viral RNA, whole blood 
was collected using a K3EDTA Greiner Vacuette tube 
(or equivalent) and centrifuged at 2500 (± 200) rela-
tive centrifugal force for 10 ± 2  min. To inactivate virus, 
plasma was treated with 3 parts (300  μl) TriReagent LS 
and samples were transferred to frozen storage (− 60  °C 
to − 90  °C), until removal for RNA extraction. Carrier 
RNA and QuantiFast High Concentration Internal Con-
trol (Qiagen) were spiked into the sample before extrac-
tion, according to manufacturer’s instructions. Viral RNA 
was eluted in AVE buffer. Each extracted RNA sample was 
tested with the QuantiFast Internal Control RT-PCR RNA 
Assay (Qiagen) to evaluate the yield of the spiked-in Quan-
tiFast High Concentration Internal Control. If the internal 
control amplified within manufacturer-designated ranges, 
further quantitative analysis of the viral target was per-
formed. RT–PCR was conducted using an ABI 7500 Fast 
Dx using primers specific to EBOV glycoprotein. Sam-
ples were run in triplicate. For quantitative assessments, 
the average of the triplicate genomic equivalents (GE) per 
reaction were determined and multiplied by 800 to obtain 
GE  ml−1 plasma. Standard curves were generated using 
synthetic RNA. %e limits of quantification for this assay 
are 8.0 × 104 − 8.0 × 1010 GE ml−1 of plasma.
Bp challenge and bacterial load determination
Rhesus macaques (n = 5 adults, 3 Female, 2 Male, weight 
5.7–6.4  kg, average age 4.8  years) were exposed using 
a head-only aerosol exposure system, the NHP were 
exposed to an average of 346/118 CFU of B. pseudomallei 
HBPUB10134a (dose range: 248–531/71–214 CFU). %is 
closely approximates the target dose of 400 CFU. All ani-
mals were exposed on the same day. Exposure durations 
ranged from 5 to 15 min. %e aerosol respiratory depo-
sition fraction was assumed to be 100%. After aerosol 
exposure, the head of each animal was wiped with a soap 
solution to remove deposited aerosol, and animals were 
housed individually under biosafety level 3 conditions. 
To facilitate collection of blood, central venous catheters 
(CVC) were placed 15–16 days prior to exposure. Blood 
was collected for baseline values and once daily for the 
first 7 days post-exposure and plasma collection for pro-
teomic evaluation occurred on Day 0 (pre-infection) and 
Days 1, 3, 5, 7, and 9 post-infection. Animals that sur-
vived the acute infection were monitored for 46–47 days 
post-exposure (study endpoint) before euthanization.
Bp bacterial load determination
Two 100 μl samples of whole blood from days 1–7, 14, 21, 
28, 35, 42 post-exposure were plated on 5% Sheep blood 
agar to detect bacteremia. Each plate was incubated 
at 37  °C for 72  h. Tissue samples from the lung, liver, 
spleen, pancreas and gonads were collected at necropsy 
under sterile conditions and cultured for bacteria. Each 
tissue sample of approximately 0.25–1.0 g was manually 
homogenized in 2 ml PBS and two 100 μl samples were 
plated on 5% Sheep blood agar (%ermo-Fisher) to evalu-
ate positive or negative growth.
Naïve NHP plasma collection
Plasma was collected from five uninfected, healthy naïve 
rhesus macaques (average age 6  years, average weight 
5.3 kg) daily for 9 days to establish a longitudinal set of 
samples.
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Plasma TMT sample preparation
Plasma samples (6 time points/animal) were first pro-
cessed in BSL-3 or BSL-4 containment by adding 25 µL 
SDS-PAGE solubilizing/reducing buffer to 75  µL sam-
ple and heating to 95  °C for 10 min. Samples were then 
removed from containment and stored at − 80  °C until 
processed by the iFASP method [28]. Briefly, 5 µL of 
each inactivated plasma sample was added to 200 µL 8 M 
Urea/100 mM Tris–HCL pH 8.5 (Solution UT8) and fil-
tered through a Microcon-30 kDa Centrifugal Filter Unit 
with an Ultracel-30 membrane (Millipore, MRCF0R030) 
at 14,000 × G for 15 min. Following several washing steps 
with 100  mM Tris pH 8.0, proteins were alkylated with 
55  mM Iodoacetamide and digested with 4  µg Trypsin/
Lys-C (Promega, V5071) overnight at 37 °C. TMT 6-Plex 
labeling (%ermo Fisher, 90061) was performed directly 
on the FASP filters per the manufacturer’s instructions. 
All 6 single labelled samples were then combined at an 
equal volume, purified by C18 spin column, dried to 
completion by speed-vac and stored at − 20 °C until ana-
lyzed by LC MS/MS.
LC–MS/MS TMT analysis
Sample digests were re-suspended in 240  μL of 0.1% 
formic acid. A Dionex 3000 RSLCnano system (%ermo 
Scientific) injected 5  μL of each digest onto a pre-
column (C18 PepMap 100, 5  μm particle size, 5  mm 
length × 0.3  mm internal diameter) using a flow rate of 
10 µL/min. %e loading solvent was 0.1% formic acid in 
HPLC grade water. Peptides were then loaded onto an 
Easy-Spray analytical column (15  cm × 75 um) packed 
with PepMap C18, 3 um particle size, 100 A porosity par-
ticles (%ermo Scientific, Inc.). A 2–38% B gradient elu-
tion in 160 min was formed using Pump-A (0.1% formic 
acid) and Pump-B (85% acetonitrile in 0.1% formic acid) 
at a flow rate of 300 nL/min. %e column eluent was con-
nected to an Easy-Spray source (%ermo Scientific) with 
an electrospray ionization voltage of 2.2 kV. An Orbitrap 
Elite mass spectrometer (%ermo Scientific, Inc.) with 
an ion transfer tube temperature of 300 °C and an S-lens 
setting of 55% was used to focus the peptides. A top 10 
data dependent MS/MS method was used to select the 
10 most abundant ions in a 400–1600  amu survey scan 
(120,000 resolution FWHM at m/z 400) with a full AGC 
target value of 1e6 ions and a maximum injection time 
of 200 ms. Higher Energy Collisional Dissociation (HCD) 
MS/MS spectra were acquired at a resolution of 30,000 
(FWHM at m/z 400) with an AGC target value of 5e4 
ions and a maximum injection time of 200 ms. %e isola-
tion width for MS/MS HCD fragmentation was set to 2 
Daltons. %e normalized HCD Collision energy was 40% 
with an activation time of 0.1 ms. %e dynamic exclusion 
duration was 30 s.
Database search and protein quantitation
Acquired MS/MS protein searches were performed with 
ProteomeDiscoverer 2.1 Sequest HT (%ermo Scien-
tific) using a Human (taxID 9606) and rhesus macaque 
subset of the SwissProt_2017_01_18 database contain-
ing 42,055 sequences, as well as a custom macaque pro-
teome developed at the University of Nebraska Medical 
Center. Sources for the custom macaque proteome data-
base included the following: MacaM genome (version 7), 
Zimin et al. [78] and NCBI. Variable modifications used 
were TMT 6-plex (N-terminal, K), Carbamyl (KMR), 
Methyl (DE), Acetyl (K), Deamidated (NQ), and Oxida-
tion (M). Cysteine carbamidomethylation was specified 
as a constant modification. %e peptide-level false dis-
covery rate (FDR) was set at 0.1% using Posterior Error 
Probability validation. Only proteins having at least 2 
Peptide Spectral Matches (PSM) were considered, with 
both unique and razor peptides used for protein quan-
titation. Normalization by total peptide amount was 
used with control channel average scaling mode turned 
on. Mass tolerances were 10 ppm for the MS1 scan and 
0.6  Da for all MS/MS scans. Quantitation results were 
filtered such that only high-confidence/unambiguous 
PSMs having MS2 isolation interference values equal to 
or less than 30% were used.
Western blot analysis
Western blot assays were performed using a mouse 
monoclonal antibody for galectin-3 binding protein 
(LGALS3BP) purchased from Origene (Cat# TA503455). 
Briefly, inactivated plasma samples (2 µl) were run under 
reducing conditions on a 4–12% precast polyacrylamide 
gel (NuPAGE bis–tris %ermo-Fisher Cat# NP0321BOX) 
and transferred to PVDF membranes. Each blot was 
blocked overnight with blocking buffer in phosphate 
buffered saline (PBS) (Cat# 37572, %ermo-Fisher) and 
then incubated with primary antibody against G3BP 
(1:500) overnight at 4  °C on a rocking platform. After 
washing 3 × with PBS + 0.1% Tween-20 for 5  min, sec-
ondary antibody (1:5000) goat α-mouse  IRDye® 680 
labelled (LICOR) was added and the blots were incubated 
an additional hour. %e blots were again washed 3 × with 
PBST, and then stored in PBS until visualized with an 
Odyssey infrared imaging system (LI-COR Biosciences 
Lincoln, NE: model number 9210).
Statistical analysis
Statistical analysis was performed with GraphPad Prism 
for Windows Version 7.00. All plasma protein abun-
dance data from serially collected plasma samples in 
response to EBOV or Bp were tested for normality using 
the Shapiro–Wilk test and log-transformed to achieve 
normal distribution if necessary. An identical test was 
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performed for the protein abundance data from naïve 
NHP. For all protein abundances with fold changes > 1.3 
in at least one post-infection time point in 40% of each 
cohort, a direct comparison was made to plasma which 
was sampled on consecutive days from naïve NHPs to 
determine significance using 2-way ANOVA. A p value 
of < 0.05 was considered significant. To compare the host-
response between NHPs exposed to EBOV or Bp, protein 
abundance ratios were compared for overlapping post-
infection time points (Days 3, 5 and 6/7 PI) using 2-way 
ANOVA. An adjustment was performed on all p-values 
for multiple comparisons using the two-stage linear step-
up procedure of Benjamini, Krieger and Yekutieli and a 
false discovery rate (FDR) of 5%. A heat map was gener-
ated which displays the average fold change value of pro-
teins for comparison of the NHP host response to EBOV 
or Bp-infection. Each entry was scaled individually to 
provide a visual representation of the relative abundance 
of each protein.
Results
Sample cohorts
As shown in Fig.  1a, the samples for this study encom-
pass 3 independent cohorts of rhesus macaques: 
EBOV-infected (n = 10), Bp-infected (n = 5), and naïve/
uninfected (n = 5). Each infected NHP sample set con-
tained a total of 6 serially collected plasma samples: 
one pre-infection (Day 0) and 5 post-infection (PI) time 
points. Plasma samples from Naïve NHP were collected 
daily over a sampling period of 9 days.
Intramuscular infection of rhesus macaques with 1000 
PFU of EBOV resulted in all NHPs becoming febrile 
between Days 3–5 PI and mortality occurred between 
Days 6 and 9 PI. Necropsy findings and gross pathological 
changes were consistent with the observations reported 
previously for EVD in NHP [30]. All non-surviving ani-
mals had positive plasma viral RNA values by Days 3 
or 4 PI (Fig. 1a and Additional file 1: Table S1). Aerosol 
infection of rhesus macaques with Bp (~ 400 CFU inhaled 
dose) resulted in symptom onset on Day 3 PI in most ani-
mals with acute infection on Days 3–13 PI. Fever (> 1.5 °C 
above baseline) was present approximately 30% of the 
time beginning on Day 2 PI in Bp-infected NHP. All ani-
mals developed significant pulmonary lesions, with 20% 
mortality (1/5); the remaining 4/5 animals developed 
chronic infection but survived until the study end-point. 
%e blood culture results for most animals in this study 
were negative (see Additional file  1: Table  S2), with the 
exception of NHPs JD27 and JH28. By histopathologic 
examination, the tissues affected most frequently were 
the lung and associated draining lymph nodes, liver and 
spleen (see Additional file 1: Table S3).
Plasma protein quantitation
To characterize the plasma proteomic response to EVD 
and melioidosis in rhesus macaques, a semi-quantita-
tive peptide tagging approach was employed to pro-
vide the relative abundance of plasma proteins in an 
analytical workflow using LC–MS/MS. For this study, 
we chose not to deplete abundant serum proteins due 
to sample volume constraints. Hence, we expected 
to identify and quantitate predominately acute phase 
reactant proteins which are part of the innate immune 
response. Serially collected EBOV-infected plasma 
samples were inactivated for removal from Bio-safety 
Laboratory level 4 (BSL-4) and processed using the 
strategy depicted in Fig. 1b. The Bp- infected samples 
were processed in an identical fashion in BSL-3 con-
tainment. On average, a total of 224 ± 36 proteins 
were identified in EBOV-infected plasma samples (see 
Fig.  2a), and similar protein total averages (218 ± 41) 
were obtained for Bp-infected plasma samples. Pro-
teins identified in each sample were analyzed for 
changes in abundance at post-infection time points by 
using the pre-infection (Day 0) sample as the baseline 
value (assigned a value of 1.0). The ratios of the inten-
sity of the reporter ions associated with the post-infec-
tion time points versus the intensity of the reporter 
ion in the pre-infection sample were acquired as rela-
tive peptide abundance. For all proteins with > 1.3 fold 
abundance change at any PI time point, a direct com-
parison was made with abundance ratios from 5 naïve 
rhesus macaques. This was done to determine the fold 
changes that were significant in the infected animals, 
and establish the natural variability of abundance for 
endogenous plasma proteins using our FASP/TMT 
strategy. For proteins that were not detected in the 
Naïve NHP data-set, abundances were considered sig-
nificantly altered if ratios were 2-fold higher or lower 
(abundance ratio of 0.5) when compared to the pre-
infection sample at any PI time point. To focus on 
the most commonly altered proteins during infection, 
we report the results of significant proteins (as com-
pared to naïve NHP levels where applicable or ≥ two-
fold altered) that were quantitated in at least 40% of 
each cohort: 4/10 EBOV-infected NHPs and 2/5 Bp-
infected NHPs. The final number of quantitated pro-
teins in each cohort is shown in Fig. 2a. Proteins with 
≥ 2 fold abundance change from pre-infection levels in 
at least one post-infection time point during EBOV or 
Bp infection in rhesus macaques are shown in Table 1a 
(EBOV data) and Table 1b (Bp data) All proteins with 
< 2 fold abundance change are listed in Table 2a (EBOV 
data) and Table 2b (Bp data).
As seen in Fig. 2a, of the 181 quantified proteins in the 
EBOV plasma samples, 19 proteins displayed ≥ 2.0  fold 
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Pathogen/exp.route NHP# survivor
Sampled: Day 
outcome
Day 0 Day 1 Day 2 Day 3 Day 4 Day5 Day 6 Day 7 Day 8 Day9
Ebola Zaire              
(1000 pfu:IM)
1509 No √ √ √ √ √ √ Euth DPE 7
1500 No √ √ √ √ √ √ Euth DPE 8
1285 No √ √ √ √ √ √ Euth DPE 9
1315 No √ √ √ √ √ √ Euth DPE 7
1305 No √ √ √ √ √ √ Euth DPE 9
1129 No √ √ √ √ √ √ Euth DPE 9
1120 No √ √ √ √ √ √ Euth DPE 6
1456 No √ √ √ √ √ √ Euth DPE 6
469 No √ √ √ √ √ √ Euth DPE 6
1000 No √ √ √ √ √ √ Euth DPE 9
Burkholderia
(300-500 cfu: Aerosol)
JD 27 No √ √ √ √ √ √ Euth DPE 13
JF18 Yes √ √ √ √ √ √ Euth DPE 46
JH28 Yes √ √ √ √ √ √ Euth DPE 46
JM 26 Yes √ √ √ √ √ √ Euth DPE 46
JP28 Yes √ √ √ √ √ √ Euth DPE 46
Naive Controls
A NA √ √ √ √ √ √ √ √ √ √
B NA √ √ √ √ √ √ √ √ √ √
C NA √ √ √ √ √ √ √ √ √ √
D NA √ √ √ √ √ √ √ √ √ √
E NA √ √ √ √ √ √ √ √ √ √
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Fig. 1 Sample complement and workflow of experimental design to track the NHP proteomic response during infection with EBOV or Burkholderia 
pseudomallei. a NHP plasma samples used for this study including designations for the first day of detectable viremia or positive blood culture 
as well as outcome. b Sample processing workflow. SDS PAGE sample buffer and heat were used to inactivate pathogens in plasma samples 
serially collected from EBOV- or Bp-infected rhesus macaques. Filter-assisted sample prep (FASP) was employed to remove the buffer and perform 
reduction/alkylation, trypsin digestion and TMT labelling. After TMT labelling, serially collected samples from each NHP were mixed together 
allowing the simultaneous analysis of samples from 6 post-infection time points in a single LC–MS/MS run
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expression change in 40% of the EBOV cohort. Of those 
19 proteins, 8 were not detectable in naïve NHP plasma 
(see Table 1a). For the Bp-infected NHPs, a total of 158 
proteins were quantitated and of these, 14 proteins exhib-
ited ≥ 2 fold abundance change in 40% of the cohort (2/5 
NHPs). Among those 14 proteins, 6 were not detectable 
in naïve plasma sets (see Table 1b). Finally, a total of 154 
proteins were quantitated in the naïve cohort and none 
displayed abundance ratios ≥ 2  fold during the 9-day 
sampling period.
As shown in Fig. 2a a total of 41 proteins displayed sig-
nificant alterations in abundance during EBOV infection 
when compared to naïve NHPs. %is list of 41 proteins 
includes the 11 with abundance changes ≥ 2 fold shown 
in Table 1a and 30 additional proteins shown in Table 2a. 
For the Bp cohort, a total of 28 proteins displayed signifi-
cantly changed expression levels when compared to naïve 
NHPs (see Tables  1b and 2b). Finally, protein levels for 
the EBOV- and Bp-infected plasma sets were compared 
for all proteins that exhibited significantly changed abun-
dances on overlapping sample collection days (Day 3, Day 
5) and Day 6/7 PI. Proteins which exhibited significantly 
different levels during EBOV- versus Bp-infection are 
shown in Table 3a, b.
a
b
*Unique proteins- redundancies in databases removed
**in at least one PI me point in 40% of cohort
*
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Infecon type
Number 
of 
idenfied 
proteins
Number of 
quantated 
proteins*
Number of 
proteins with 
>2 fold Δ in 
abundance** 
Number of proteins 
with significant change 
in abundance 
compared to naïve NHP
EBOV 224 181 19 41
Bp 218 158 14 28
Uninfected Naïve 203 154 0 NA
Fig. 2 Overview of protein identification/quantitation results and major acute phase protein levels in rhesus macaques infected with EBOV or Bp. 
a Number of proteins quantitated, and number of significant protein alterations in EBOV and Bp-infected plasma samples when compared to naïve 
NHP. b–d The relative protein abundances (y-axis) of b alpha-1 anti-trypsin member 3 (A1AT3), c C-reactive protein (CRP), and d serum amyloid A2 
(SAA2) detected in plasma during EBOV or Bp infection are plotted versus post-infection day (x-axis). For all three proteins, similar maximum fold 
change increases were observed between the two infection types but different temporal kinetics contributed to higher levels observed at Day 3 
and Day 6 PI for A1AT3, and Day 3 for CRP and SAA2 in the Bp-infected NHP. Abundance levels that were significantly different from levels found in 
naïve NHPs are designated with a black border around the symbol and levels that were significantly different between EBOV- and Bp-infected NHPs 
are designated with an asterisk (*). Statistical significance was based on 2-way ANOVA analysis
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Table 2 Proteins with  < 2  fold alteration with  signi"cant abundance change in  (a) at  least 4/10 EBOV infected NHP 
when compared to naive NHP, (b) at least 2/5 Bp infected NHP when compared to naive NHP
Accession Description # NHP quant. Average CV % Abundance ratio—Day PI p Value 
versus naive—Day PI
Day 2 Day 3 Day 4 Day 5 Day 6 Day 4 Day 5 Day 6
AFM_173 Afamin 9 1 1.00 1.02 1.00 0.83 0.79 0.0406 0.0005 0.0002
ALB_213 Albumin 10 0.73 1.01 1.10 0.92 0.76 0.67 0.0441 0.0002 0.0002
SERPINA1_5265 Alpha-1 antitrypsin member 1 10 0.61 0.99 1.03 1.12 1.30 1.37 NS 0.0002 0.0002
APOA2_336 Apolipoprotein A-II 7 2.1 1.09 0.90 0.77 0.59 0.55 0.0065 0.0011 0.0002
APOB_338 Apolipoprotein B48 10 1.8 1.02 0.94 0.94 1.15 1.61 NS 0.0091 0.0002
APOC3_345 Apolipoprotein C-III 6 3 0.99 0.92 0.63 0.67 0.77 0.0132 0.0024 0.0033
APOH_350 Apolipoprotein H 6 1.6 1.03 1.03 0.82 0.60 0.59 0.0020 0.0002 0.0002
SERPING1_710 C1 inhibitor member 1 10 0.34 0.98 0.98 1.06 1.14 1.37 NS 0.0106 0.0002
CPN2_1370 Carboxypeptidase N subunit 2 6 1.3 0.95 1.04 1.01 1.11 1.43 NS NS 0.0012
CP_1356 Ceruloplasmin (ferroxidase) 10 1 1.00 1.04 1.14 1.29 1.42 NS 0.0436 0.0023
C1S_716 Complement C1S subcomponent 6 1.3 0.97 1.01 1.20 1.48 1.69 NS NS 0.0133
C2_717 Complement component 2 6 1.1 0.98 0.97 1.01 1.17 1.60 NS NS 0.0135
C9_735 Complement component 9 10 1.2 1.06 1.02 1.15 1.44 1.58 0.0106 0.0007 0.0004
CFB_629 Complement factor B 10 1.8 1.03 1.07 1.28 1.55 1.90 0.0095 0.0002 0.0002
FGA_2243 Fibrinogen alpha chain 10 0.64 1.00 1.02 1.26 1.38 1.10 0.0413 0.0183 NS
FGB_2244 Fibrinogen beta chain 10 0.5 0.97 1.03 1.22 1.46 1.07 NS 0.0051 NS
FGG_2266 Fibrinogen gamma chain 10 0.62 1.04 1.02 1.22 1.39 1.17 0.0295 0.0031 NS
FN1_2335 Fibronectin 1 10 1.1 0.99 0.93 0.75 0.74 0.78 0.0023 0.0033 0.0095
FETUB_26998 Fetuin B 8 1.8 0.91 0.97 0.83 0.62 0.60 NS 0.0195 0.0320
HRG_3273 Histidine rich glycoprotein 10 0.71 0.97 0.96 0.84 0.71 0.60 0.0514 0.0050 0.0003
ITIH1_3697 Inter-alpha-trypsin inhibitor HC 1 10 0.44 0.98 0.91 0.87 0.80 0.68 0.0022 0.0002 0.0002
ITIH2_3698 Inter-alpha-trypsin inhibitor HC 2 10 0.8 0.98 0.97 0.96 0.73 0.64 0.0307 0.0013 0.0002
ITIH3_3699 Inter-alpha-trypsin inhibitor HC 3 10 0.53 0.99 1.02 1.03 1.18 1.40 NS 0.0062 0.0004
ITIH4_3700 Inter-alpha-trypsin inhibitor HC4 10 1.2 1.00 1.01 1.10 1.21 1.36 NS NS 0.0037
KNG1_3827 Kininogen 1 6 2 0.98 1.03 0.85 0.63 0.52 NS 0.0078 0.0005
LUM_4060 Lumican 8 1.3 1.02 0.96 0.71 0.60 0.68 NS 0.0418 0.0066
PLG_5340 Plasminogen 10 1 0.95 1.00 0.91 0.74 0.67 NS 0.0008 0.0003
TF_7018 Transferrin 10 0.61 0.99 1.00 0.95 0.82 0.70 0.0389 0.0002 0.0002
TTR_7276 Transthyretin 10 0.6 0.95 0.88 0.82 0.74 0.80 0.0498 0.0128 0.0497
GC_2638 Vitamin D binding protein 10 0.84 1.03 1.03 0.97 0.82 0.77 NS 0.0033 0.0007
Accession Description # NHP quant. Average CV % Abundance ratio—Day PI p Value versus naive—Day PI
Day 1 Day 3 Day 5 Day 7 Day 9 Day 3 Day 5 Day 7 Day 9
AFM_173 Afamin 5 3.5 1.10 0.85 0.82 0.69 0.77 0.0209 0.0051 0.0006 0.0007
ALB_213 Albumin 5 3.3 0.96 0.77 0.63 0.61 0.57 0.0307 0.0025 0.0009 0.0025
SERPINA1_5265 Alpha-1 antitrypsin 
member 1
5 7.5 1.19 1.49 1.86 1.77 1.89 0.0297 0.0071 0.0025 0.0058
APOA1_335 Apolipoprotein A-I 5 3.2 1.13 0.81 0.59 0.54 0.55 NS 0.0229 0.0101 0.0095
APOH_350 Apolipoprotein H 5 8.2 0.86 0.63 0.62 0.65 0.69 0.0002 0.0002 0.0002 0.0002
CPN2_1370 Carboxypeptidase N 
subunit 2
3 3.4 1.20 1.33 1.57 1.56 1.59 0.0011 0.0006 0.0002 0.0002
CP_1356 Ceruloplasmin (fer-
roxidase)
5 4.8 1.05 1.32 1.62 1.59 1.73 0.0354 0.0025 0.0018 0.0023
C3_718 Complement compo-
nent 3
5 2.9 1.03 1.22 1.29 1.37 1.30 NS 0.0068 0.0008 0.0038
C4A_720 Complement compo-
nent 4A
5 4.6 1.22 1.31 1.52 1.35 1.22 0.0307 0.0022 0.0094 NS
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Acute phase plasma proteins with comparable abundance 
changes during EBOV or Bp infection
For visualization of the datasets, a heat map was con-
structed using the average fold change values for all pro-
teins which exhibited significant alteration during EBOV 
or Bp infection (see Fig. 3). %e proteins are divided up 
into categories to aid in the reporting of the results and 
facilitate the comparison of the NHP plasma proteomic 
response to EBOV or Bp infection. %e fold change val-
ues for each protein represented in the heat map can be 
found in Tables  1a/b and 2a/b. In general many acute 
phase plasma proteins were altered to comparable lev-
els during EBOV or Bp infection in NHP. However, we 
observed differences in the temporal kinetics of the 
proteomic response, in that for most of the quantitated 
proteins, the Bp-infected animals displayed abundance 
changes 1 day earlier than the EBOV-infected NHP (i.e. 
Day 3 PI vs. Day 4 PI in the EBOV NHP).
Acute phase proteins, such as C-reactive protein 
(CRP), Serum Amyloid A2 (SAA2), and Lipopolysac-
charide binding protein (LPS-BP) were increased several 
fold in both infection types, but were not present at high 
enough levels to be quantitated in the naive NHP plasma 
samples (see Fig.  2 and Table  1a, b). %e major acute 
phase proteins Alpha-1 antitrypsin (A1AT) members 1 
and 3, Haptoglobin, Hemopexin, Alpha-1 acid glycopro-
tein, CRP, and SAA2 reached comparable maximum fold 
change values at the common post-infection time-points 
between the infection types. However, fold change values 
at the early (Day 3) or late (Day 6/7) PI time-points were 
often statistically significant between the two cohorts. 
For example, as shown in Fig. 2b, levels of A1AT3 in the 
Bp cohort were significantly higher than levels found in 
the EBOV cohort on Day 3 PI, but both infection types 
reach similar abundance levels on Day 4/5 PI (see Fig. 3 
and Table 1a, b). A1AT3 levels continued to increase in 
the EBOV cohort through Day 6 PI but remained rela-
tively static in the Bp cohort. %e levels of most positive 
acute phase proteins in Bp-infected NHP reached a max-
imum between Days 3–5 PI, at which point they either 
plateaued or exhibited decreased abundance. %is may 
indicate a resolution of the acute response to Bp infec-
tion, since 4/5 Bp-infected animals survived to the end-
point of the study (Day 46 PI). As seen in Fig. 2c, d, CRP 
and SAA2 levels rose dramatically in Bp-infected NHP, 
but a decline is observed afterward over the course of the 
sampling period. In contrast, in EBOV-infected NHP, lev-
els of SAA and CRP began to increase on Day 3 or 4 PI, 
and reached maximum levels on Day 5 or 6 PI. Overall 
a higher amount of variability was observed in the pro-
tein abundance data obtained from the Bp cohort, espe-
cially for CRP and SAA2, indicating a larger variation in 
the host response of these animals as compared to the 
EBOV-infected cohort. %is is in agreement with previ-
ous studies of melioidosis in rhesus macaques and other 
NHP species which have reported moderate-to-severe, 
variable disease presentation [24, 26, 27].
Table 2 (continued)
Accession Description # NHP quant. Average CV % Abundance ratio—Day PI p Value versus naive—Day PI
Day 1 Day 3 Day 5 Day 7 Day 9 Day 3 Day 5 Day 7 Day 9
C5_727 Complement compo-
nent 5
5 3.0 1.27 1.14 1.36 1.33 1.46 NS 0.0043 0.0068 0.0009
C9_735 Complement compo-
nent 9
5 5.3 1.06 1.36 1.57 1.62 1.61 NS 0.0033 0.0004 0.0024
CFB_629 Complement factor B 5 4.8 0.97 1.26 1.30 1.35 1.26 0.0155 0.0015 0.0125 0.0498
FGG_2266 Fibrinogen gamma chain 5 3.3 0.90 1.60 1.79 1.88 1.88 0.0005 0.0002 0.0002 0.0010
FN1_2335 Fibronectin 1 5 5.1 0.99 0.71 0.78 0.78 0.78 0.0002 0.0002 0.0012 NS
HPX_3263 Hemopexin 5 7.9 0.96 1.44 1.55 1.79 1.53 0.0118 0.0029 0.0039 0.0420
HRG_3273 Histidine rich glycopro-
tein
5 5.3 1.01 0.80 0.60 0.56 0.56 0.0418 0.0002 0.0002 0.0002
ITIH2_3698 Inter-alpha-trypsin inhibi-
tor HC 2
4 3.3 0.95 0.71 0.68 0.66 0.62 0.0183 0.0013 0.0004 0.0005
ITIH3_3699 Inter-alpha-trypsin inhibi-
tor HC 3
5 7.3 1.08 1.25 1.51 1.47 1.59 0.0227 0.0093 0.0094 0.0070
ITIH4_3700 Inter-alpha-trypsin inhibi-
tor HC 4
5 4.8 1.07 1.25 1.58 1.49 1.41 NS 0.0010 0.0004 0.0031
LRG1_116844 Leucine-rich alpha-2-gly-
coprotein 1
4 7.7 1.09 1.73 1.75 1.63 1.54 Not quantitated in naive NHP 
plasma
TF_7018 Transferrin 5 2.5 1.02 0.90 0.85 0.86 0.84 NS 0.0035 0.0219 0.0141
NS not signi"cant
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In summary, the levels of the major acute phase reac-
tant proteins A1AT1, A1AT3, haptoglobin, hemopexin, 
A1AGP, CRP and SAA2 were increased in response to 
EBOV or Bp infection. In EBOV-infected NHPs, there 
was a slightly delayed time dependent increase for 
these acute phase reactant proteins, but the change in 
Table 3 Plasma proteins with signi"cant abundance di#erences during EBOV versus Bp infection (a) in NHP (b) that are 
attributed to a temporal di#erences in the host response
Protein description p Value EBOV versus Bp Trend
Day 3 Day 5 Day 6/7
Actin, cytoplasmic 2 NS NS 0.0129 Higher in EBOV
Apo B48 0.0129 0.0017 0.0004 Higher in EBOV
Apo E NS NS 0.0008 Higher in EBOV
Ceruloplasmin 0.0057 0.0128 NS Higher in Bp
Clusterin NS NS 0.0004 Higher in EBOV
Comp factor B NS NS 0.0130 Higher in EBOV
Complement C1r NS 0.1501 0.0173 Higher in EBOV
Complement C2 NS NS 0.0111 Higher in EBOV
Complement C3 NS 0.0543 0.0292 Higher in Bp
Complement C4A 0.0137 0.0004 0.0004 Higher in Bp
Complement C4B 0.0103 0.0028 0.0004 Higher in Bp
Complement C5 NS 0.0015 0.0101 Higher in Bp
Fibrinogen alpha 0.0010 0.0037 0.0004 Higher in Bp
Fibrinogen beta 0.0004 0.0010 0.0004 Higher in Bp
Fibrinogen gamma 0.0014 0.0026 0.0004 Higher in Bp
Galectin-3 binding protein NS NS 0.0200 Higher in EBOV
Leucine-rich alpha-2 glycoprotein 1 NS 0.0057 0.0014 Higher in EBOV
S100 calcium binding protein A9 NS NS 0.0253 Higher in EBOV
Protein description p Value EBOV versus Bp
Day 3 Day 5 Day 6/7
A1AT member 1 0.0015 0.0142 0.1004
A1AT member 3 0.0156 NS 0.0328
Afamin 0.0137 NS NS
Albumin 0.0066 NS NS
Apo H 0.0004 NS NS
Complement C9 0.0230 NS NS
C-reactive protein 0.0253 NS NS
Fibronectin-1 0.0004 NS NS
Hemopexin NS NS 0.0161
Inter-alpha-trypsin inhibitor heavy chain 1 0.0027 NS NS
Inter-alpha-trypsin inhibitor heavy chain 3 0.0419 0.0230 NS
Inter-alpha-trypsin inhibitor heavy chain 4 NS 0.0111 0.0556
Plasminogen NS NS 0.0014
Serum amyloid A2 0.0004 NS NS
Fig. 3 Heat map representing the protein abundance differences observed between EBOV and Bp infection. The protein abundance ratio values 
taken from Tables 1a/b and 2a/b were individually scaled to aid in the visualization of the protein abundance differences observed between EBOV 
and Bp infected plasma. This was done by assigning the lowest ratio values between the 2 sets to light green and the highest to bright red. As a 
result the heat map illustrates the general trending expression of each class of proteins. Proteins designated with an asterisk (*) had levels that were 
significantly different based on a 2-way ANOVA test between the two cohorts for at least one common post-infection time-point
(See figure on next page.)
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abundance was comparable to Bp infected animals. All 
plasma proteins with abundance differences between the 
two infection types attributed to temporal kinetics are 
shown in Table 3b.
Acute phase plasma proteins with di$ering abundance 
levels during EBOV or Bp infection
Fibrinogen is a soluble plasma protein synthesized in 
hepatocytes. %ree separate genes encode three distinct 
polypeptide chains (α, β and γ) forming a homodimer 
which circulates in the blood and aids in clot forma-
tion [31]. In diseases associated with vascular disrup-
tion, infection or inflammation, the blood concentration 
of fibrinogen increases several fold and is considered 
an acute phase protein [45]. Furthermore, an expand-
ing body of evidence suggests that fibrinogen acts as a 
mediator of inflammation by interacting with different 
cell types through cell-specific receptors to induce spe-
cific inflammatory functions [32]. An increase in Fibrino-
gen α, β, and γ chains was observed in both EBOV- and 
Bp-infected NHP plasma. However, the levels of all three 
Fibrinogen polypeptides were significantly higher in Bp-
infected NHPs (see Figs.  3 and 4). As seen in Table  1b, 
and Fig.  4a, b, on Day 3 PI Fibrinogen α and β were 
increased 2.3 and 1.9  fold respectively in Bp-infected 
NHPs, and Fibrinogen γ abundance levels (see Table 2b) 
were increased 1.6 fold. Although Fibrinogen α, β, and γ 
levels were also increased in EBOV-infected NHPs (see 
Table  2a), the maximum fold change increase was only 
≈ 1.4 on Day 5 PI. Not surprisingly, Fibrinogen levels in 
the EBOV-infected animals returned to baseline levels 
on Day 6 PI, which is likely a result of Fibrinogen con-
sumption as EVD progresses. As shown in Table 3a, the 
increased abundance observed for Fibrinogen α, β, and 
γ in the Bp cohort was significantly higher than levels 
found in the EBOV NHP cohort for all of the overlapping 
time points (Days 3, 5 and 6/7 PI).
Levels of Ceruloplasmin (CP) or ferroxidase were also 
higher in Bp-infected animals. CP is an acute phase reac-
tant that increases in concentration in serum/plasma 
during infection and inflammation [27, 28]. As shown in 
Table 2a, CP abundance increased to significant levels in 
the EBOV-infected NHPs on Days 5 and 6 PI. Bp-infected 
NHPs displayed a significant increase in abundance on 
Days 3 and 5 PI and the level of CP increased to a maxi-
mum of 1.7  fold on Day 9 PI (see Table  2b). CP levels 
were significantly higher in the Bp cohort on Day 3 PI 
(p = 0.0057) and Day 5 PI (p = 0.0128) when compared to 
EBOV-infected NHPs (see Table 3a and Additional file 1: 
Figure S1).
%e calcium binding proteins S100A8 and S100A9 are 
secreted into circulation by neutrophils and form a het-
erocomplex (calprotectin) which is involved in a wide 
range of cellular processes of innate immunity against 
microbial invaders [33]. During infection and/or tissue 
injury their levels are markedly increased [46, 47]. In 
EBOV-infected NHPs, S100A9 was increased 8.43 fold 
from pre-infection levels by Day 6 PI, and S100A8 lev-
els increased by 4.95  fold (Table  1a). A comparison 
with the naïve cohort could not be performed since 
neither protein was detected in plasma from unin-
fected animals. In the Bp-infected cohort, S100A9 was 
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Fig. 4 Higher plasma fibrinogen levels were observed during Bp infection when compared to EBOV infection in macaques. Levels of a fibrinogen 
alpha and b fibrinogen beta were significantly lower in plasma samples collected from rhesus macaques during EBOV infection when compared 
to Bp-infected animals. Abundance levels that were significantly different from levels found in naïve NHPs are designated with a black border 
around the symbol and levels that were significantly different between EBOV- and Bp-infected NHPs are designated with an asterisk (*). Statistical 
significance was based on 2-way ANOVA analysis
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quantitated in only 2/5 animals and a maximum fold 
change of 5.85 was observed on Day 9 PI (Table 1b). As 
seen in Fig. 3, and Additional file 1: Figure S1, in com-
parison with Bp-infected NHPs, S100A9 levels were 
significantly higher in EBOV-infected animals on Day 
6 PI (Table 3a, p = 0.0253). Unfortunately, S100A8 was 
quantitated in only 1 Bp-infected NHP, and a maxi-
mum fold increase of 1.57 was observed on Day 9 PI for 
this animal. %erefore, the levels of both S100A8 and 
S100A9 were higher in EBOV-infected NHP at Day 6/7 
PI in comparison to Bp-infected animals.
Leucine-Rich Alpha-2-Glycoprotein 1 (LRG1) is 
expressed during neutrophilic granulocyte differentiation 
and is involved in protein–protein interactions, signal 
transduction, and cell adhesion [34]. LRG1 was not quan-
titated in the naïve cohort, but in EBOV-infected animals 
a 3.9-fold increase on Day 5 PI was observed (see Fig. 5a 
and Table  1a). In the Bp cohort, LRG1 was increased 
1.7 fold on Day 3 PI (see Table 2b), and when comparing 
LRG1 levels in EBOV- and Bp-infected NHPs, significant 
p-values were obtained for Days 5 and 6 PI (see Table 3a 
and Fig. 5a), confirming a higher level in EBOV-infected 
animals for LRG1 at these time-points.
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Fig. 5 Leucine-rich alpha-2 glycoprotein 1 (LRG1) and galectin-3 binding protein (G3BP) increase during EBOV infection in rhesus macaques. 
Neither protein was quantitated in naïve NHP plasma a Leucine-rich alpha-2 glycoprotein (LRG1) abundance levels increased to > 3 fold on Day 5 
PI during EBOV infection whereas, Bp-infected NHPs exhibited a very slight increase. LRG1 levels were significantly higher in EBOV-infected animals 
on Days 5 and 6/7 PI (indicated with * symbol, based on 2-way ANOVA analysis). b G3BP abundance increased in EBOV-infected NHPs by > 2.5 fold 
on Day 6 PI, and was only quantitated in 1/5 Bp-infected animals. c Representative data from EBOV-infected NHP 1000 depicting Western blot 
confirmation of the FASP/TMT increased abundance of G3BP observed during EBOV infection. Equal volumes of plasma (5 μl) were loaded for each 
sample. No bands are visible in plasma from Bp-infected NHP JD27, confirming baseline levels and no increase during Bp infection. d FASP/TMT 
quantitation for G3BP for NHP 1000 (EBOV-infected: filled circle) and NHP JD27 (Bp-infected: filled square)
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Plasma levels of Galectin-3 binding protein (G3BP), 
also known as Lectin galactoside-binding soluble-3 bind-
ing protein, were significantly higher in EBOV-infected 
rhesus macaques when compared to Bp-infected ani-
mals. G3BP was detected and quantitated in 7/10 EBOV-
infected NHPs but was quantitated in only 1 Bp-infected 
animal, and was not quantitated in any plasma sample 
from the naïve cohort. In EBOV-infected animals G3BP 
increased 2.6 fold by Day 6 PI (see Table 1a and Fig. 5b). 
Although the ANOVA comparison between the 7 EBOV- 
and 1 Bp-infected NHPs indicated that there was a signif-
icantly higher abundance of G3BP on Day 6 PI in EBOV 
infected NHP (see Table 3a), due to a lack of G3BP TMT 
quantitation in 4/5 Bp-infected plasma sets, an orthogo-
nal confirmation was undertaken. Western blot analysis 
was performed on 5 EBOV plasma sets and 3 Bp plasma 
sets using a G3BP specific monoclonal antibody. A time-
dependent increase in G3BP protein abundance on Days 
4-6 PI was confirmed in the EBOV-infected plasma (see 
Fig. 5c). Conversely, G3BP was not detected by Western 
blot in any of the Bp plasma sets. %e increase in G3BP 
expression in EBOV-infected plasma observed via west-
ern blot was comparable to the TMT/MS relative abun-
dance shown in Fig.  5d for EBOV-infected NHP 1000, 
whereas in Bp-infected NHP JD27, G3BP levels remained 
close to pre-infection levels throughout sampling period. 
All 5 EBOV-infected plasma sets tested for G3BP via 
Western blot, exhibited the same trend of increased 
abundance.
In summary, Fibrinogen and CP levels were signifi-
cantly higher in Bp-infected NHP when compared to 
EBOV-infected animals. Additionally, there is a time 
dependent increase in the expression of the plasma 
proteins S100A8, S100A9, LRG1 and G3BP in EBOV-
infected NHP while the Bp infected cohort showed no 
significant induction of these proteins, suggesting a path-
ogen specific host response.
Cellular proteins
Some cellular/non-secreted proteins exhibited signifi-
cant differences in abundance during the late phase of 
EBOV (Day 6) infection in comparison to Bp infection. 
For example, in EBOV-infected NHPs, cytoplasmic 
Actin levels reached a 4.4 fold increase on Day 6 PI (see 
Table 1a). Conversely, Actin levels in Bp-infected animals 
reached only 1.2  fold increase from the pre-infection 
level on Day 5 PI (data not shown). %erefore as seen in 
Fig. 3 and Table 3a, Actin levels in EBOV-infected NHP 
plasma were significantly higher than the levels found in 
Bp-infected NHPs on Day 6/7 PI (p = 0.0129). %is dif-
ference most likely reflects a higher level of cell death 
occurring late in EBOV infection, ultimately leading 
to an increase in circulating actin levels. Similarly, the 
abundance level of Clusterin in EBOV-infected NHPs 
was significantly elevated on Days 5 and 6 PI and when 
compared to levels in Bp-infected NHP, were higher on 
Day 6/7 PI (p = 0.0004, see Table 3a). Clusterin is associ-
ated with the clearance of cellular debris and apoptosis; 
as such, it is not surprising that increased levels of this 
protein were detected in plasma from NHPs in the mid-
to late stages of EVD.
Apolipoproteins
Decreased levels of circulating apolipoproteins in human 
patients with sepsis correlate with the severity of infec-
tion [35], indicating that lipoprotein metabolism is 
strongly influenced by infection, inflammation and sepsis 
[36]. %e Apolipoproteins A-1, A-II, and B are generally 
considered negative acute phase reactants [37, 38]. Dur-
ing EVD in rhesus macaques, we observed decreased lev-
els of Apo A1 (see Additional file 1: Figure S2) and Apo 
AII, however, an increase in the levels of Apo-B100 and 
Apo-B48 was observed. Due to RNA editing, the Apo B 
protein occurs in plasma in 2 main isoforms. Apo-B48 
and ApoB100 share a common N-terminal sequence, 
but ApoB48 lacks ApoB100’s C-terminal LDL recep-
tor binding region [39]. In EBOV-infected plasma a sig-
nificant increase was observed for ApoB100 at Day 5 PI 
(p = 0.0022) and Day 6 PI (p = 0.0003) (see Table 1a and 
Fig. 6a). Unfortunately, Apo B100 was only quantitated in 
1/5 Bp-infected NHPs and in that animal, a decrease of 
1.8 fold was observed on Day 5 PI (see Fig. 6a). Levels of 
Apo B48 increased on Days 5 and 6 PI in EBOV-infected 
NHPs (see Table 2a and Fig. 6b), whereas Apo B48 abun-
dance dropped below baseline levels in Bp-infected 
NHPs. %is drop in Apo B48 abundance was not signifi-
cant when compared to the uninfected cohort, but as 
shown in Table 3a, Bp-infected plasma levels of ApoB48 
were significantly lower than the EBOV-infected NHPs 
on Days 3, 5 and 6/7 PI.
Levels of Apolipoprotein E (Apo E) are often elevated 
in adult and pediatric patients during bacterial infection 
and sepsis [40, 41]. As shown in Table 1a, abundance lev-
els of Apo E in EBOV-infected NHPs reached a 2.50 fold 
increase on Day 6 PI. In contrast, as seen in Fig. 6c, the 
maximum average fold change for Apo E in the Bp cohort 
was 1.24  fold on Day 5 PI, and therefore Apo E levels 
were significantly higher in EBOV-infected animals on 
Day 6 PI (p = 0.0008, see Table 3a, Figs. 3 and 6c).
Along with Apo A-1 and Apo A-II mentioned above, 
Apo A-IV, Apo CIII, and Apo H (β2-glycoprotein) abun-
dance levels were significantly reduced in both EBOV-
infected and Bp-infected NHPs. With the exception of 
Apo H which exhibited significantly lower levels in the 
Bp-infected NHP on Day 3 PI due to an earlier response, 
no significant difference was observed for the levels of 
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these Apolipoproteins between EBOV- and Bp-infected 
NHPs at any PI time point. %erefore, in summary, 
during EVD in rhesus macaques, Apo B100, ApoB48, 
and Apo E increase in expression and reach higher fold 
change values than the Bp-infected NHP, whereas Apo 
A1, Apo AII, Apo A4, Apo CIII and Apo H act as negative 
acute phase reactants in both infection types with com-
parable reductions.
Complement cascade components
Multiple proteins involved in the complement cascade 
were identified and quantitated in plasma from EBOV- 
and Bp-infected NHPs, and many abundance differences 
were observed between the two cohorts. Levels of the 
complement protein C1r were significantly increased 
in EBOV-infected NHPs on Days 5 and 6 PI (Table 1a). 
As seen in Fig.  7a, C1r levels in Bp-infected NHPs did 
increase marginally on Days 3 and 5 PI, but this increase 
was not significant from levels in naïve animals. %e 
increase of C1r in the EBOV cohort was significantly dif-
ferent from levels in the Bp cohort on Days 5 and 6 PI 
(see Table 3a). Also increased in abundance in the EBOV-
infected NHPs were Complement components C1s and 
C2 on Day 6 PI (Table  2a and Additional file  1: Figure 
S2B/C). %e level of C2 continued to rise in EBOV-
infected NHP and was significantly higher on Day 6 PI 
than levels in the Bp-infected animals which remained 
close to baseline (p = 0.0111 see Table 3a).
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Fig. 6 Altered apolipoprotein levels during EBOV or Bp infection in rhesus macaques. Abundance levels of Apo B100 (a), Apo B48 (b) and Apo E (c) 
were increased in EBOV-infected NHPs on Days 5 and 6 PI. No increase was observed for these proteins in Bp-infected NHPs. d Apo CIII abundance 
was reduced significantly during EBOV infection, whereas only a slight decrease in abundance was observed in Bp-infected NHPs. Abundance 
levels that were significantly different from levels found in naïve NHPs are designated with a black border around the symbol and levels that were 
significantly different between EBOV- and Bp-infected NHPs are designated with an asterisk (*). Statistical significance was based on 2-way ANOVA 
analysis
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Major differences in Complement component 4 (C4) 
levels were observed between EBOV- and Bp-infected 
rhesus macaques. C4 is a polymorphic serum protein 
consisting of two isoforms, C4A and C4B, which are 
encoded by two separate genes located within chro-
mosome 6p on the major histocompatibility complex 
(MHC class III) in both humans and macaques [42, 
43]. Complement C4B exhibited the largest abundance 
increase compared to other complement components 
in Bp-infected NHPs, reaching a 2 fold increase by Day 
7 PI (see Table  1b). Unfortunately, this protein was 
not quantitated in the naïve cohort. In EBOV-infected 
NHPs, C4B levels were actually reduced 1.3  fold from 
the pre-infection level (ratio = 0.75) on Day 6 PI. As 
seen Fig. 7b, although the levels of C4B in the Bp cohort 
had larger variation, the abundance increase was signif-
icant from levels observed in the EBOV cohort for Days 
3, 5 and 6/7 PI, (p = 0.0103, 0.0028 and 0.0004 respec-
tively: see Table 3a). Levels of C4A were also higher in 
the Bp-infected cohort. As seen in Table 2b and Fig. 7c, 
C4A abundance was increased significantly in Bp-
infected plasma by Day 5 PI, (p = 0.0022 see Table 2b). 
Conversely, C4A levels in the EBOV cohort were not 
significantly different from the naïve cohort at any time 
point, and therefore were significantly lower than the 
C4A abundance observed in the Bp-infected cohort, 
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Fig. 7 Comparison of complement protein abundance in plasma during EBOV- or Bp-infection in rhesus macaques. a Abundance levels of 
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especially for Days 5 and 6/7 PI (p = 0.0004, see Fig. 7c 
and Table 3a).
In addition to C4A and C4B, levels of complement 
components C5 and C3 were also significantly higher in 
Bp-infected NHPs when compared to EBOV-infected 
NHPs. As shown in Fig. 7d, on Days 5 and 6/7 PI, C5 lev-
els were significantly higher in Bp-infected animals when 
compared to EBOV-infected NHPs (see also Table  3a, 
Fig. 3), and when comparing C3 abundance, Bp-infected 
animals displayed significantly higher levels on Day 6/7 
PI (see Additional file 1: Figure S2(D)).
Complement proteins Factor B and component C9 
were increased in both the Bp- and EBOV-infected 
NHP on Days 3–5 PI. In EBOV-infected NHPs Factor 
B rose to a significant level on Day 4 PI (p = 0.0095, see 
Table 2a and Additional file 1: Figure S3(A)), and on Day 
6 PI, reached a maximum increase of 1.9 fold. In the Bp-
infected cohort, Factor B was increased modestly from 
Day 3 to Day 5 PI, and dropped slightly on Day 6 PI (see 
Table  2b). Due to the continued increase of Factor B 
observed in the EBOV-infected NHPs, levels of this pro-
tein were significantly higher on Day 6 when compared 
to Bp-infected animals (p = 0.0130, see Table  3a). Com-
plement C9 abundance rose in both cohorts during infec-
tion (see Additional file  1: Figure S3(B)), and reached a 
similar maximum. Due to the difference in host response 
kinetics, levels of C9 in the Bp cohort were significantly 
higher when compared to levels observed in the EBOV 
cohort on Day 3 PI only (p = 0.023, see Table 3b).
Classic negative acute phase plasma proteins
Classic negative acute phase proteins were quantitated 
in both the EBOV- and Bp-infected NHP. For example, 
Albumin was reduced significantly in EBOV- and Bp-
infected animals (see Table  2a, b), and was significantly 
lower in the Bp cohort on Day 3 PI (p = 0.0066, see 
Table  3b), but the EBOV cohort reached a comparable 
reduction on Days 5-7 PI. Similarly, levels of Transfer-
rin, Afamin, Fetuin A (Alpha-2-HS Glycoprotein), Fetuin 
B and Transthyretin were reduced in both infection 
types, and no statistical difference was found between 
their levels. Levels of Fibronectin 1 were significantly 
reduced in both infection types, and reached compara-
ble reductions, but due to an earlier drop in levels in the 
Bp-infected animals, levels of Fibronectin 1 were signifi-
cantly lower when compared to the EBOV-infected NHP 
on Day 3 PI (p = 0.0004 see Table 3b and Additional file 1: 
Figure S3C).
%e inter-alpha (globulin) inhibitor (ITI) family (also 
known as the family of inter-alpha-trypsin inhibitors) is 
composed of serine protease inhibitor proteins that are 
assembled from two precursors: a light chain and either 
one or two heavy chains [44, 45]. During infection and 
inflammation, ITI family members can act as both posi-
tive and negative acute phase reactants under various dis-
ease conditions including sepsis and cancer [46, 47]. We 
detected and quantitated inter-alpha (globulin) inhibi-
tor H1, H2, H3 and H4 during EBOV and Bp infection 
in rhesus macaques. In this study, ITIH1, ITIH2, were 
found to be negative acute phase reactants while ITIH3, 
and ITIH4 acted as positive acute phase proteins during 
both infection types in NHPs (see Fig.  3, Tables  1b and 
2a).
In summary for most negative acute phase proteins, 
comparable reductions were observed in both infection 
types. %is includes, Albumin, Fibronectin 1, the Fetuins 
A/B, and the inter-alpha-trypsin inhibitors ITIH1 and 
ITIH2.
Discussion
Our approach to the characterization of the rhesus 
macaque plasma host response to infection is novel in 
comparison with other studies because we have 1) sam-
pled naïve NHP to better define the variability of acute 
phase proteins during the sampling period, and 2) com-
pared the rhesus proteomic response in two different 
infection types (EVD vs. melioidosis). %e NHP host 
response to EBOV infection has been reported in previ-
ous studies employing transcriptomic approaches, and 
a few of these studies have detected upregulated gene 
expression before the appearance of symptoms [9, 48]. 
However, no comparison was made with other infection 
types and therefore the specificity of the transcriptomic 
response is unknown. Comparative analysis from previ-
ous published studies indicates that although some pro-
teins involved in the acute phase response (APR) exhibit 
similar trends of altered expression in multiple infection 
types, the fold changes exhibited for certain proteins are 
quite different depending on the pathogenic agent [49]. 
Our data supports this finding and therefore future inves-
tigations hold promise for the identification and develop-
ment of panels of human APR proteins which may have 
expression patterns that are unique for infection types or 
disease states.
%e observed differences in the plasma temporal 
response between EBOV- and Bp-infected NHPs is most 
likely due to the faster replication rate of Bp versus EBOV 
and the different infection routes used for exposure (aer-
osol vs. IM). %ese differences resulted in some protein 
abundance differences between the two infection cohorts 
at the early (Day 3) or late (Day 6/7) overlapping PI time 
points. Accordingly, some of the protein differences 
observed between the two infection types may be attrib-
uted to the immune cells which encounter the pathogen 
first, leading to the activation of different cellular signal-
ing outcomes.
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Most of the host proteins quantitated displayed altered 
abundance levels by Day 4 or 5 PI in EBOV-infected rhe-
sus macaques. %is is concurrent with detectable viremia 
and development of pyrexia in most of the animals. We 
noted that animals with an early onset of fever (by Day 
3 PI) also had altered protein levels beginning on Day 3 
PI. %is phenomenon is in agreement with a recent tran-
scriptomic study showing cytokine gene expression is 
concurrent with the onset of fever in EVD [9]. Interest-
ingly, in some NHP, alteration of host response protein 
levels occurred before pyrexia and detectable viremia. 
For example, NHP 0469 presented with fever and detect-
able viremia on Day 4 PI (see Additional file 1: Table S1), 
but on Day 3 PI the abundance of LRG1 was increased 
1.6  fold for this animal. Since our proteomic approach 
was untargeted, it may be possible to detect altered 
expression at earlier pre-symptomatic time points using a 
targeted LC–MS/MS approach.
Our comparison of the plasma host response to EBOV 
and Bp infection has important implications for efforts 
to discriminate viral from bacterial infections in human 
samples. Levels of CRP and SAA have been reported to 
be significantly higher in some bacterial infections when 
compared to viral infections [50–53]. In this study, CRP 
and SAA abundance in Bp-infected animals was signifi-
cantly higher than levels found in EBOV-infected NHPs 
only for Day 3 PI due to a difference in host response 
kinetics. At the later common time points of Day 5 PI 
and Day 6/7 PI there was no significant difference in CRP 
or SAA levels. It can be argued that the pathogenicity of 
EBOV infection puts EVD in an entirely different class 
than typical viral infections, since the level of these acute 
phase proteins has been reported to increase with dis-
ease severity [54]. %erefore the observed levels of CRP 
and SAA during EVD in rhesus macaques may be higher 
than what would be expected from an infection caused 
by some common respiratory viruses.
Ceruloplasmin (CP) levels were significantly higher in 
Bp-infected NHP on Day 3 and 5 PI when compared to 
EBOV-infected animals. CP is a multi-copper oxidase 
that is secreted from the liver, involved in iron homeo-
stasis, and accounts for 95% of the copper content of the 
serum [55]. CP is also an acute phase protein induced in 
response to inflammation, trauma, or infection with bac-
teria, viruses and protozoans [56–58]. Since CP is a fer-
roxidase, it has been proposed that the increased level of 
this protein during bacterial infections is part of an innate 
immune strategy to mobilize iron from tissues to starve 
invading bacterial pathogens of essential iron nutrients 
[59]. %us, the observation in our data that plasma CP 
levels are higher during Bp infection versus EBOV infec-
tion is in line with this theory and suggests a pathogen 
specific response.
Both LRG1 and G3BP were increased significantly 
during EVD in rhesus macaques, when compared to Bp-
infected NHP. LRG1 is an acute phase protein that is pro-
duced by hepatocytes after IL-6 induction and secreted 
from neutrophils after activation [60]. Levels of LRG1 
are increased in many inflammatory conditions includ-
ing sepsis, appendicitis, rheumatoid arthritis and cancer. 
%erefore, the higher level of LRG1 may indicate that the 
degree of inflammation (and neutrophil activation) dur-
ing infection is greater in EBOV-infected animals than 
in Bp-infected animals. G3BP is a secreted glycoprotein, 
and although all of its biological functions are not yet 
fully understood, it has been observed to promote cell-
to-cell adhesion, stimulate host-defense against viruses 
and may be a surrogate biomarker for type 1 interferon-
dependent gene activation [61–63]. G3BP is upregulated 
in many cancers and during infection with several viruses 
such as HIV, Hepatitis C, Dengue and Hantavirus [64–
67]. Our data is in agreement with anti-viral host defense 
functions, since increased expression was observed dur-
ing EBOV, but not Bp infection. Using ELISA quantita-
tion, Hepojoki et al. found a significant increase in G3BP 
levels in serum samples from cynomolgus macaques 
during Hantavirus infection beginning on Day 7 or 8 PI 
[65]. Additionally, analysis of plasma samples collected 
from human patients with acute Hantavirus or Dengue 
infection showed higher G3BP levels when compared to 
healthy controls [66]. G3BP abundance increases have 
also been reported during inflammatory conditions such 
as rheumatoid arthritis and systemic lupus erythema-
tosus, suggesting that chronic bacterial infection could 
also induce G3BP due prolonged inflammation. %ere-
fore, the examination of plasma at later time points dur-
ing the chronic phase of Bp infection will be necessary 
to determine if G3BP is increased. Although both LRG1 
and G3BP are not filovirus-specific induced proteins, the 
increased level produced may be useful as blood-based 
markers to distinguish infection types (bacterial vs. viral) 
during the acute phase.
Plasma fibrinogen levels in Bp-infected NHPs were 
significantly higher than levels found in EBOV-infected 
animals. In a transcriptomic analysis reported in 2017 by 
Liu et al., some of the most highly differentially expressed 
genes during EBOV infection in humans were fibrino-
gen alpha, beta, and gamma [68]. Likewise, Ebihara et al. 
found increased fibrinogen levels in rhesus macaques on 
Days 4 and 5 of EBOV infection which strikingly declined 
at the terminal stages of EVD [69]. Plasma fibrinogen lev-
els are known to decline due to the conversion of fibrino-
gen to fibrin, and EVD causes coagulopathy resembling 
disseminated intravascular coagulation (DIC) at the ter-
minal stages of disease [70]. However, since fibrinogen is 
an acute phase reactant produced by the liver, increased 
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levels during inflammation and infection may mask 
fibrinogen consumption during clot formation. In this 
study, fibrinogen α, β, and γ were increased during EBOV 
infection beginning on Day 4 PI and reverted to baseline 
by Day 6 PI. %e increase in fibrinogen protein levels was 
much higher in Bp-infected NHPs beginning on Day 3 PI 
and remained high through Day 9 PI. Generally, by Day 
4 of EVD in rhesus macaques, macrophages, monocytes, 
dendritic cells, and fibroblasts are infected, but serum 
chemistry alterations, petechia and uncontrolled hem-
orrhage usually do not manifest until after Day 4 PI [69, 
71]. Additionally, abnormal coagulation measurements 
(i.e. Prothrombin time: PT and Activated Partial %rom-
boplastin Time: APTT) have been reported to peak 
between Days 6 and 10 PI during EBOV infection in rhe-
sus macaques [71]. Collectively, this evidence indicates 
that the lower fibrinogen level observed during EVD 
when compared to Bp infection is not the result of fibrin-
ogen consumption on Days 4 or 5 PI, while the drop in 
fibrinogen levels observed on Day 6 PI may be the result 
of fibrinogen conversion to fibrin. Additionally, although 
hepatocytes are usually infected by Day 3 or 4 PI during 
EVD [72], widespread liver damage does not typically 
appear at this stage of the infection. %erefore fibrino-
gen abundance observed on Day 4 PI is most likely not 
affected by a decline in hepatocyte production. Although 
we observed other acute phase reactants and markers of 
inflammation to be highly upregulated in EBOV-infected 
NHPs, the lower level of Fibrinogen in EVD in compari-
son with Bp-infected NHPs is not easily explained. Given 
the evidence of highly upregulated Fibrinogen transcripts 
during EBOV infection in humans, it is tempting to spec-
ulate that the virus is somehow able to suppress the pro-
duction of the fibrinogen proteins in circulating plasma.
Our data from NHPs during EVD is in agreement with 
the lipoprotein alterations observed during sepsis, in that 
plasma levels of Apo A1 were reduced while Apo E levels 
increased. In this study true sepsis was not observed in 
the Bp-infected animals, since only 1/5 NHPs had a posi-
tive blood culture, and therefore we observed only a slight 
increase in Apo E abundance. It has been reported that 
triglyceride levels increase by at least fivefold in EBOV-
infected rhesus macaques, but total cholesterol changes 
are negligible [71]. %e increase of Apo B we observed dur-
ing EBOV infection is likely a direct result of the increase 
in chylomicron particles carrying plasma triglycerides.
Increases in levels of proteins relevant to all three com-
plement pathways were observed during EBOV and Bp 
infection in rhesus macaques. %e ongoing identifica-
tion of novel mechanisms of viral antagonism of compo-
nents of the complement system highlights the important 
role of these pathways in innate immunity. For example, 
the NS1 glycoprotein of some Flaviviruses (i.e. Dengue, 
West Nile and Yellow fever), which is expressed on the 
surface of and secreted by infected cells, can suppress 
complement by recruiting and activating C1s and C4BP 
to promote cleavage of C4 and inactivate C4B [73]. Addi-
tionally, both soluble and membrane-bound NS1 proteins 
of Dengue and West Nile viruses have been reported to 
interact with the complement regulatory component fac-
tor H, resulting in decreased deposition of C3 and C5b-9 
membrane attack complexes on cell surfaces [74]. Our 
data indicates that the levels of complement components 
C1r, C1s, C2, C9 and factor B are significantly increased 
in plasma during EBOV infection. While there was a 
slight non-significant increase in the abundance level 
of C3 and C5. Conversely, Bp-infected NHPs displayed 
increases in C3, C4A, C4B, C5 and C9, which were signif-
icantly higher than those found in EBOV-infected NHPs. 
It is possible that excess complement activation lead 
to the consumption of C3, C4 (A/B) and C5 in plasma 
during EVD, or the lower levels observed for these pro-
teins may indicate an antagonism of complement com-
ponents, specifically those downstream of C1 and C2, 
by the EBOV virus. An antagonistic strategy that causes 
the downregulation of the proinflammatory chemoat-
tractants (C3A, C4A and C5A) in plasma during EBOV 
infection would lead to a reduced influx of inflammatory 
cells into infected sites, potentially contributing to EVD 
pathogenesis.
Conclusions
In conclusion, plasma proteomic analysis uncovered spe-
cific differences in acute phase protein levels induced 
during EVD or melioidosis in rhesus macaques. %ese 
differences reflect the global circulating innate immune 
response to a highly pathogenic viral or bacterial agent 
in relevant NHP models of infection. Most notable in our 
results is the higher level of fibrinogen and complement 
proteins C3, C4, and C5 exhibited by Bp-infected NHPs, 
while EBOV-infected animals displayed higher levels 
of two glycoproteins: LRG1 and G3BP. Future studies 
examining the plasma proteomic host response of rhesus 
macaques to other infection types endemic to the same 
regions where EBOV and Bp are prevalent will facilitate 
the identification and development of a panel of plasma 
host proteins that could be used to differentiate infection 
types. %ese panels could then be validated using human 
samples to determine the diagnostic potential.
Additional "le
Additional &le 1. Supplementary tables and figures.
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